- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.09. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 03.09. | Cognition Therapeutics, Inc.: Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target | 155 | GlobeNewswire (Europe) | PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 02.09. | Cognition Therapeutics schließt registrierte Direktplatzierung über 30 Millionen US-Dollar ab | 2 | Investing.com Deutsch | ||
| 02.09. | Cognition Therapeutics closes $30 million registered direct offering | 2 | Investing.com | ||
| 02.09. | Cognition Therapeutics, Inc.: Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) | 2 | GlobeNewswire (USA) | ||
| 28.08. | Cognition Therapeutics: Aktie bricht nach 30-Millionen-Dollar-Direktplatzierung ein | 1 | Investing.com Deutsch | ||
| 28.08. | Cognition Therapeutics stock falls after $30 million direct offering | 1 | Investing.com | ||
| 28.08. | Cognition Therapeutics launches $30M share offering | 2 | Seeking Alpha | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock | 8 | GlobeNewswire (USA) | ||
| 26.08. | Cognition Therapeutics regains Nasdaq compliance on $1.00 bid price rule | 1 | Seeking Alpha | ||
| 26.08. | Cognition Therapeutics regains Nasdaq compliance with $1 share price | 2 | Investing.com | ||
| 26.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | 164 | GlobeNewswire (Europe) | PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 26.08. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Cognition Therapeutics stock jumps after FDA confirms Phase 3 design | 7 | Investing.com | ||
| 13.08. | Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug | 2 | Benzinga.com | ||
| 12.08. | Cognition Therapeutics aligns with FDA on Alzheimer's drug phase 3 design | 16 | Investing.com | ||
| 12.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease | 264 | GlobeNewswire (Europe) | - Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:... ► Artikel lesen | |
| 07.08. | Cognition Therapeutics GAAP EPS of -$0.11 misses by $0.01 | 2 | Seeking Alpha | ||
| 07.08. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,15 | +2,16 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CUREVAC | 4,618 | -0,09 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| AMGEN | 259,55 | +0,72 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,315 | +0,29 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 134,85 | +0,67 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,745 | +2,21 % | Novo Nordisk, Eli Lilly oder Viking Therapeutics: Wer gewinnt den Dreikampf? | Der Markt für Adipositas-Medikamente boomt - und die Konkurrenz zwischen den Schwergewichten Novo Nordisk und Eli Lilly prägt das Geschehen. Doch während sich die Giganten duellieren, könnte das viel... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,515 | +3,74 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 79,00 | +1,28 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,196 | -2,55 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,240 | +2,02 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| BIOMARIN PHARMACEUTICAL | 47,070 | +1,38 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 33,700 | +0,48 % | Exelixis Q2 2025: Cabozantinib-Franchise wächst um 19 %, Markteinführung bei NET gewinnt an Fahrt |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.